Skip to main content
SpringerLink
Log in

Cyclosporin Maintenance Monotherapy After Renal Transplantation

What Factors Predict Success?

  • Disease Management
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

The use of cyclosporin monotherapy as maintenance immunosuppression in primary cadaveric renal transplant recipients is not popular except in a few European centres. Corticosteroid withdrawal is becoming more popular, and is usually attempted with the newer immunosuppressants which have a more corticosteroid-sparing effect than cyclosporin. The adverse effects and morbidity associated with maintenance regimens consisting of 2 or 3 immunosuppressive drugs are well known, but the potential benefits of cyclosporin monotherapy must be balanced against an increased risk of graft loss by rejection.

We selected patients for a trial of corticosteroid withdrawal and subsequent cyclosporin monotherapy. These patients received an individually designed immunosuppressive regimen with careful control of cyclosporin trough concentrations. The cyclosporin formulations used were its original oil-based solution or gelatin capsule (Sandimmun®, Sandimmune®) until mid-1996 and then the microemulsion formulation (Neoral®).

Corticosteroid withdrawal was attempted in 89% of patients with a graft functioning at 3 months after transplantation and was effective in 88% of them. At a mean follow-up time of 98 ± 23 months, 69% of grafts were functioning and 92% of patients were alive. 50% of patients with a functioning graft were receiving long term cyclosporin monotherapy. Mild rejection episodes occurred in 6% of patients receiving cyclosporin monotherapy per year of treatment, and chronic rejection caused graft loss in 1.4% of patients per year of treatment.

Comparison of successful and unsuccessful outcomes allows us to define favourable predictive factors. For corticosteroid withdrawal these are: older recipient age, lower creatininaemia at months 6 and 8 and higher trough cyclosporin concentrations at month 6. For cyclosporin monotherapy these are: later timing of azathioprine withdrawal, recipient age >25 years, donor age ≤40 years, creatininaemia ≤125 μmol/L at initiation of monotherapy and no rejection episode before initiation of monotherapy.

We have observed a low incidence of nonmelanoma skin cancers and of squamous-cell carcinoma in our series. This is perhaps the result of the azathioprinesparing effects of the regimen (7 azathioprine-free years per patient with successful cyclosporin monotherapy, and 4 azathioprine-free years per patient with unsuccessful monotherapy). This important point will need further studies but is encouraging.

Maintenance cyclosporin monotherapy is feasible and probably useful in selected primary graft recipients without deleterious effects on overall results in terms of graft and patient survival. Careful patient selection using the predictive factors we have defined should make cyclosporin monotherapy more effective, allowing the present 57% success rate at 5 years post-transplantation to be increased by 15 or 20%.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Salaman JR. Cyclosporin mono-drug therapy. Transplant Proc 1988; 20: 117–20

    PubMed  CAS  Google Scholar 

  2. Salaman JR. Low dose cyclosporine monotherapy v. combinationtherapies. In: Touraine, JL. Transplantation and clinicalimmunology 1989. Amsterdam: Elsevier, 1989: 73–84

    Google Scholar 

  3. Salaman JR. Cyclosporine monotherapy - who needs it? ClinExp Perspect Sandimmun Ther 1991; 1: 1–4

    Google Scholar 

  4. Schleibner S, Schneeberger H, Hillebrand G, et al. Cyclosporinemonotherapy. An ideal long term immunosuppression? Transplant Proc 1990; 22: 1695–6

    PubMed  CAS  Google Scholar 

  5. Tarantino A, Aroldi A, Stucchi L, et al. A randomized prospectivetrial comparing cyclosporine monotherapy with tripledrug therapy in renal transplantation. Transplantation 1991;52: 53–7

    Article  PubMed  CAS  Google Scholar 

  6. Tamm M, Thiel G, Huser B, et al. Cyclosporine monotherapyafter kidney transplantation since 1983. Transplant Proc 1991; 23: 997–8

    PubMed  CAS  Google Scholar 

  7. Thiel G, Bock A, Spondlin M, et al. long term benefits and risksof cyclosporine A (Sandimmune). An analysis at 10 years.Transplant Proc 1994; 26: 2493–8

    PubMed  CAS  Google Scholar 

  8. Park K, Kim ST, Lee SR, et al. A 1-year prospective randomizedstudy in Korean living donor kidney transplant recipients: comparing cyclosporine monotherapy andcyclosporine/prednisolone during the maintenance phase ofimmunosuppression. Transplant Proc 1994; 26: 1985–6

    PubMed  CAS  Google Scholar 

  9. Margreiter R, Bösmüller C, Spielberger M, et al. Cyclosporinemonotherapy after cadaveric renal transplantation. TransplantProc 1989; 11: 1591–3

    Google Scholar 

  10. Morales JM, Munoz Cepada MA, Sancho S, et al. Cyclosporine(cya) alone as therapy of maintenance in renal transplants (rt)patients over fifty years old: a prospective study [abstract]. JAm Soc Nephrol 1991; 2: 509

    Google Scholar 

  11. Morales JM, Sancho S, Munoz MA, et al. Cyclosporine monotherapyin patients over 50 years of age after renal transplantation: short term results. Transplant Proc 1992; 24: 37–8

    PubMed  CAS  Google Scholar 

  12. Johnson RWG, Mallick NP, Scott PD, et al. Prospective trialswith cyclosporine monotherapy in cadaver renal transplantation.J Nephrol 1990; 4: 47–9

    CAS  Google Scholar 

  13. Johnson RWG. Primary regimens in immunosuppression.Nephrol Dial Transplant 1995; 10: 101–4

    PubMed  CAS  Google Scholar 

  14. Griffin PJA, Ross WB, Williams JD, et al. Low dose cyclosporinemonotherapy in renal transplantation. Transplant Proc 1987; 5: 3685

    Google Scholar 

  15. Griffin PJA, Salaman JR. Long term results of cyclosporinemonotherapy in kidney transplantation. Transplant Proc 1991; 23: 992–3

    PubMed  CAS  Google Scholar 

  16. Opelz G, Collaborative Transplant Study. Effect of the maintenanceimmunosuppressive drug regimen on kidney transplantoutcome. Transplantation 1994; 58: 443–6

    Article  PubMed  CAS  Google Scholar 

  17. Bertoni E, Zanazzi M, Rosati A, et al. long term steroid sideeffects in renal transplantation need a safe steroid withdrawal: a single-center experience. Transplant Proc 1998; 30: 1303–4

    Article  PubMed  CAS  Google Scholar 

  18. Gulanikar AC, Belistky P, MacDonald AS, et al. Randomizedcontrolled trial of steroids versus non steroids in stablecyclosporine-treated renal graft recipients. Transplant Proc 1991; 23: 990

    PubMed  CAS  Google Scholar 

  19. Johnson RWG, Mallick NP, Bakran A, et al. Cadaver renaltransplantation without maintenance steroids. TransplantProc 1989; 21: 1581–2

    CAS  Google Scholar 

  20. Lloveras J, Puig JM, Comerma I, et al. Requirements for safeprednisolone discontinuation in late renal transplantation inrecipients immunosuppressed with cyclosporine. TransplantProc 1990; 22: 1693–4

    CAS  Google Scholar 

  21. Maiorca R, Cristinelli L, Brunori G, et al. Prospective controlledtrial of steroid withdrawal after six months in renal transplantpatients treated with cyclosporine. Transplant Proc 1988; 20Suppl. 3: 121–5

    PubMed  CAS  Google Scholar 

  22. Stratta RJ, Armbrust MJ, Oh CS, et al. Withdrawal of steroidimmunosuppression in renal transplant patients. Transplantation 1988; 45: 323

    Article  PubMed  CAS  Google Scholar 

  23. Stratta RJ. Experience with azathioprine withdrawal after simultaneouskidney-pancreas transplantation. Transplant Proc 1998; 30: 1353–4

    Article  PubMed  CAS  Google Scholar 

  24. Hegner I, Binswanger U, Cyclosporine A monotherapy comparedto azathioprine: cyclosporine A double therapy in longterm immunosuppression after kidney allotransplantation[abstract]. Kidney Int 1995; 47: 975

    Google Scholar 

  25. Touchard G, Cogny F, Hurault de Ligny B, et al. Maintenancecyclosporine monotherapy in primary cadaver renal transplants.Results of a French collaborative group study: Angers,Caen, Limoges, Poitiers, Reims, Tours [abstract]. J Am SocNephrol 1991; 2, 820

    Google Scholar 

  26. Touchard G, Hauet T, Cogny Van Weydevelt F, et al. Maintenancecyclosporine A monotherapy in primary cadaver renaltransplant: complementary results of a multicentric study.Kidney Int 1994; 46: 1242–3

    Article  Google Scholar 

  27. Kupin W, Venkat KK, Oh HK, et al. Complete replacement ofmethylprednisolone by azathioprine in cyclosporine-treatedprimary cadaveric renal transplant recipients. Transplantation 1988; 45: 53–5

    Article  PubMed  CAS  Google Scholar 

  28. Hricik DE, Mayes JT, Schulak JA. Independent effects ofcyclosporine and prednisone on post transplant hypercholesterolemia.Am J Kidney Dis 1991; 18: 353

    PubMed  CAS  Google Scholar 

  29. Hricik DE, Whalen CC, Lautman J, et al. Withdrawal of steroidsafter renal transplantation. Clinical predictors of outcome.Transplantation 1992; 53: 41–5

    Article  PubMed  CAS  Google Scholar 

  30. Hricik DE, Bartucci MR, Moir EJ, et al. Effects of steroidwithdrawal on postransplant diabetes mellitus in cyclosporine-treatedrenal transplant recipients. Transplantation 1991; 51: 374

    Article  PubMed  CAS  Google Scholar 

  31. Ponticelli C, Tarantino A, Segaloni GP, et al. Italian multicentrestudy group for renal transplantation. A randomized studycomparing three cyclosporine-based regimens in cadavericrenal transplantation. J Am Soc Nephrol 1997; 8: 638–46

    PubMed  CAS  Google Scholar 

  32. Tejani A, Khalid MH, Rajpoot D, et al. Strategies for optimizinggrowth in children with kidney transplants. Transplantation 1989; 47: 229

    Article  PubMed  CAS  Google Scholar 

  33. Reisman L, Lieberman KV, Burrows L, et al. Follow-upcyclosporine treated pediatric renal allograft recipients aftercessation of prednisone. Transplantation 1990; 49: 76

    Article  PubMed  CAS  Google Scholar 

  34. Wolpaw TM, Deal CL, Fleming-Brooks S, et al. Factors influencingvertebral bone density after renal transplantation.Transplantation 1994; 58: 1186

    PubMed  CAS  Google Scholar 

  35. Hricik DE, O’Toole MA, Schulak JA, et al. Steroid-free immunosuppressionin cyclosporine-treated renal transplant recipients: a meta-analysis. J Am Soc Nephrol 1993; 4: 130

    Google Scholar 

  36. Hricik DE. Steroid withdrawal in renal transplant recipients: pro point of view. Transplant Proc 1998; 30: 1380–2

    Article  PubMed  CAS  Google Scholar 

  37. Ponticelli C, Opelz G. Are corticosteroids really necessary inrenal transplantation? Nephrol Dial Transplant 1995; 10: 1587–91

    PubMed  CAS  Google Scholar 

  38. Brown MW, Forwell MA. Rejection reaction after stopping prednisolonein kidney transplant recipients taking cyclosporine.N Engl J Med 1986; 314: 183

    Article  PubMed  CAS  Google Scholar 

  39. Opelz G. Superior long term kidney graft survival in patients onmaintenance immunosuppression with cyclosporine and azathioprine.Transplant Proc 1993; 25: 1289–90

    PubMed  CAS  Google Scholar 

  40. Bouma GD, Hollander DAMJ, Van Der Meer-Prins, et al. Invitro sensitivity to prednisolone may predict kidney rejectionafter steroid withdrawal. Transplantation 1996; 62: 1422-9

    Article  PubMed  CAS  Google Scholar 

  41. Touchard G, Hauet T, Cogny Van Weydevelt F, et al. Maintenancecyclosporine monotherapy after renal transplantation: clinical predictors of long term outcome. Nephrol Dial Transplant 1997; 12: 1956–60

    Article  PubMed  CAS  Google Scholar 

  42. Hurault de Ligny B, Toupance O, Lavaud S, et al. Facteursprédictifs de succès à long terme de la cyclosporine enmonothérapie d’entretien après transplantation rénale [abstract].1er Congrès francophone de recherche clinique etbiologique en transplantation. 1996 Dec 5–6, Paris

  43. Goldman MH, Davis B, Cruz E, et al. Effects of azathioprinewithdrawal in kidney recipients with stable function two yearsafter transplant. Clin Transplant 1996; 10: 617–9

    PubMed  CAS  Google Scholar 

  44. Schneeberger H, Zanker B, Hillebrand G, et al. Tacrolimus asa primary immunosuppressive therapy in cadaveric renaltransplantation: five years’ experience at a single center.Transplant Proc 1998; 30: 1598–9

    Article  PubMed  CAS  Google Scholar 

  45. Shapiro R, Jordan ML, Scantlebury VP, et al. Outcome aftersteroid withdrawal in renal transplant patients receivingtacrolimus-based immunosuppresion. Transplant Proc 1998;30: 1375–7

    Article  PubMed  CAS  Google Scholar 

  46. Grewal HP, Thistlethwhite JR, Loss GE, et al. Corticosteroidcessation 1 week following renal transplantation usingtacrolimus/mycophenolate mofetil based immunosuppression.Transplant Proc 1998; 30: 1378–9

    Article  PubMed  CAS  Google Scholar 

  47. Calne RY, Wood AJ. Cyclosporine in cadaveric renal transplantation: 3 year follow-up of a European multicentre trial. Lancet 1985; II: 549

    Article  Google Scholar 

  48. Hillebrand G, Schneeberger H, Schleibner S, et al. Ten yearsexperience with cyclosporine monotherapy after renal transplantation.Transplant Proc 1993; 25: 513–4

    PubMed  CAS  Google Scholar 

  49. Land W. Cyclosporine in cadaveric renal transplantation: fiveyears follow up results of the European multicentre trial.Transplant Proc 1988; 20: 73–84

    PubMed  CAS  Google Scholar 

  50. Hurault de Ligny B, Toupance O, Lavaud S, et al. Factors predictingthe long term success of maintenance cyclosporinemonotherapy after kidney transplantation. Transplantation. Inpress

  51. Terasaki PI. Ed. UCLA Tissue Typing Laboratory, Los Angeles, California. Clinical Transplants 1988; 409–33

  52. Wang H, Solez K, Kjellstrand CM, et al. The importance ofdonor vascular pathology in determining renal allograft outcome[abstract]. J Am Soc Nephrol 1998; 9: 702A

    Google Scholar 

  53. Andreu J, Campistol JM, Oppenheimer F, et al. Monotherapywith cyclosporine in kidney transplantation. Transplant Proc 1990; 22: 2270–1

    PubMed  CAS  Google Scholar 

  54. Andreu J, Campistol JM, Oppenheimer F, et al. Cyclosporinemonotherapy as primary immunosuppression in renal transplantation.Five year experience. Transplant Proc 1994; 26: 337–40

    PubMed  CAS  Google Scholar 

  55. Opelz G. CTS Collaborative Transplant Study Newsletter 1996; 5

  56. Ratcliffe PJ, Dudley CRK, Firth JD, et al. Randomised controlledtrial of steroid withdrawal in renal transplant recipientsreceiving triple immunosuppression. Lancet 1996;348: 643–8

    Article  PubMed  CAS  Google Scholar 

  57. Ben-Maimon CS, Burke JF, Besarab A, et al. Evidence againstchronic progressive cyclosporine nephrotoxicity. TransplantProc 1991; 23: 1260–2

    CAS  Google Scholar 

  58. Burke JF, Pirsch JD, Ramos EL, et al. long term efficacy andsafety of cyclosporine in renal-transplant recipients. N Engl JMed 1994; 331: 358–63

    Article  Google Scholar 

  59. Lewis RM. long term use of cyclosporine A does not adverselyimpact on clinical outcomes following renal transplantation.Kidney Int 1995; 48: S75–8

    Google Scholar 

  60. Aikawa A, Sells RA, Ward RG, et al. Retrospective study ofrenal transplantation with cyclosporine monotherapy. TransplantProc 1992; 24: 1694–5

    CAS  Google Scholar 

  61. Opelz G. Collaborative Transplant Study Newsletter 1993; 4

  62. Griffin PJA, Ferguson CJ, Ross WB, et al. A controlled trial ofazathioprine in combination with cyclosporine in cadavericrenal transplantation. Transplant Proc 1990; 22: 1369

    PubMed  CAS  Google Scholar 

  63. Canadian Multicenter Transplant Study Group. A randomizedclinical trial of cyclosporine in cadaveric renal transplantation.N Engl J Med 1983; 309: 809–15

    Article  Google Scholar 

  64. Canadian Multicenter Transplant Study Group. A randomizedclinical trial of cyclosporine in cadaveric renal transplantation.Analysis at three years. N Engl J Med 1986;314: 1219–25

    Article  Google Scholar 

  65. Gjertson DW, Cecka JM, Terasaki PL. The relative effects ofFK506 and cyclosporine on short and long term kidney graftsurvival. Transplantation 1995; 60: 1384–8

    Article  PubMed  CAS  Google Scholar 

  66. Turka LA. What’s new in transplant immunology: problemsand prospects. Ann Intern Med 1998; 128: 946–8

    PubMed  CAS  Google Scholar 

  67. Hourmant M, Buzelin F, Dubigeon P, et al. High long term graftsurvival rates in kidney transplantation with the seqential associationof antithymocyte globulin and cyclosporine Amonotherapy. Transplant Proc 1987; 19: 2113–4

    PubMed  CAS  Google Scholar 

  68. Klare B, Strom TM, Hahn H, et al. Remarkable long terni prognosisand excellent growth in kidney transplant children undercyclosporine montherapy. Transplant Proc 1991; 23: 1013–7

    PubMed  CAS  Google Scholar 

  69. Arias M, Cereira P, Piazza JJ, et al. Cyclosporine monotherapyversus triple therapy in steady state renal transplant patients;cardiovascular risk factors (Multicentric Study) [abstract].Kidney Int 1992; 44: 1424

    Google Scholar 

  70. Kiberd A. Cyclosporine-induced renal dysfunction in humanrenal allograft recipients. Transplantation 1989; 48: 965–9

    Article  PubMed  CAS  Google Scholar 

  71. Berg KJ, Holdaas H, Endresen L, et al. Effects of isradipine onrenal function in cyclosporin-treated renal transplanted patients.Nephrol Dial Transplant 1991; 6: 725–30

    PubMed  CAS  Google Scholar 

  72. Propper DJ, Whiting PH, Power DA, et al. The effect of nifedipineon graft function in renal allograft recipients treated withcyclosporine A. Clin Nephrol 1989; 32: 62–7

    PubMed  CAS  Google Scholar 

  73. Murer L, Giacomini A, Gambaro G, et al. long term treatmentwith CsA decreases INF-γ mRNA and increases pre-pro-ET1mRNA in rat kidneys. Transplant Proc 1998; 30: 950–1

    Article  PubMed  CAS  Google Scholar 

  74. Asberg A, Christensen H, Hartmann A, et al. Diltiazem modulatescyclosporin A induced renal hemodynamic effects butnot its effect on plasma endothelin-1. Clin Transplant 1998;12: 363–70

    PubMed  CAS  Google Scholar 

  75. Kon V, Sugiura M, Inagami T, et al. Role of endothelin incyclosporine-induced glomerular dysfunction. Kidney Int 1990; 37: 1487–91

    Article  PubMed  CAS  Google Scholar 

  76. Provencher PH, Saltis J, Funder JW. Glucocorticoids but notmineralocorticoids modulate endothelin-1 and angiotensin IIbinding in SHR vascular smooth muscle cells. J SteroidBiochem Mol Biol 1995; 52: 219–25

    Article  CAS  Google Scholar 

  77. Stanimirovic DB, McCarron RM, Spatz M. Dexamethasonedown-regulates endothelin receptors in human cerebromicrovascularendothelial cells. Neuropeptides 1994; 26: 145–52

    Article  PubMed  CAS  Google Scholar 

  78. Laporte J, D’Orleans-Juste P, Singh G, et al. Dexamethasoneand phosphoramidon inhibit endothelin release by culturednonciliated bronchiolar epithelial (Clara) cells. J CardiovascPharmacol 1995; 26: S53–5

    CAS  Google Scholar 

  79. Calderon E, Gomez-Sanchez CE, Cozza EN, et al. Modulationof endothelin-1 production by a pulmonary epithelial cellline. I. Regulation by glucocorticoids. Biochem Pharmacol 1994; 48: 2065–71

    Article  PubMed  CAS  Google Scholar 

  80. Vittori E, Marini M, Fasoli A, et al. Increased expression ofendothelin in bronchial epithelial cells of asthmatic patientsand effect of corticosteroids. Am Rev Respir Dis 1992; 146: 1320–5

    PubMed  CAS  Google Scholar 

  81. Wagner OF, Christ G, Wojta J, et al. Polar secretion of endothelin-1by cultured endothelial cells. J Biol Chem 1992;267: 16066–8

    PubMed  CAS  Google Scholar 

  82. Glover MT, Deeks JJ, Raftery MJ, et al. Immunosuppressionand risk of non-melanoma skin cancer in renal transplant recipients.Lancet 1997; 349: 398–9

    Article  PubMed  CAS  Google Scholar 

  83. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long termimmunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporine regimens.Lancet 1998; 351: 623–8

    Article  PubMed  CAS  Google Scholar 

  84. Confavreux C, Saddier P, Grimaud J, et al. Risk of cancer fromazathioprine therapy in multiple sclerosis: a case controlstudy. Neurology 1996; 46: 1607–12

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nephrology Unit, Centre Hospitalier Universitaire, Poitiers, France

    Guy Touchard, Cathy Verove, Frank Bridoux & Marc Bauwens

Authors
  1. Guy Touchard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cathy Verove
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Frank Bridoux
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marc Bauwens
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Touchard, G., Verove, C., Bridoux, F. et al. Cyclosporin Maintenance Monotherapy After Renal Transplantation. BioDrugs 12, 91–113 (1999). https://doi.org/10.2165/00063030-199912020-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-199912020-00002

Keywords

Search

Navigation